Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle

Nanotechnology

Volumn 20, Issue 37, 2009, Pages

  Roa, Wilson ^a   Zhang, Xiaojing ^a   Guo, Linghong ^a   Shaw, Andrew ^a   Hu, Xiuying ^a   Xiong, Yeping ^b   Gulavita, Sunil ^c   Patel, Samir ^a   Sun, Xuejun ^a   Chen, Jie ^b   Moore, Ronald ^a   Xing, James Z ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE; CELL CYCLE REGULATION; CELL SURVIVAL; CLONOGENIC ASSAYS; GOLD NANOPARTICLES; GROWTH INHIBITION; HUMAN PROSTATE CANCER CELLS; PROPIDIUM IODIDE; PROSTATE CANCER CELLS; RADIATION SENSITIVITY; RADIO-SENSITIZATION; WESTERN BLOTTING;

FLOW CYTOMETRY; GLUCOSE; IONIZING RADIATION; NANOPARTICLES;

CELL MEMBRANES;

CESIUM 137; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; GLUCOSE; GLUCOSE CAPPED GOLD NANOPARTICLE; GOLD NANOPARTICLE; PROTEIN P53; UNCLASSIFIED DRUG; GOLD; METAL NANOPARTICLE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; CELL CYCLE; CHEMISTRY; DRUG EFFECT; FLOW CYTOMETRY; MALE; PROSTATE TUMOR; RADIATION EXPOSURE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; GLUCOSE; GOLD; HUMANS; MALE; METAL NANOPARTICLES; PROSTATIC NEOPLASMS;

EID: 70349101328     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/20/37/375101     Document Type: Article

References (35)

1. Kawasaki E S and Player A 2005 Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer Nanomed. Nanotechnol. 1 101-9
2. Alivisatos A P 2001 Less is more in medicine-sophisticated forms of nanotechnology will find some of their first real-world applications in biomedical research, disease diagnosis and, possibly, therapy Sci. Am. 285 66-73
3. Liu G D and Lin Y H 2005 A renewable electrochemical magnetic immunosensor based on gold nanoparticle labels J. Nanosci. Nanotechnol. 5 1060-5
4. Jordan A et al 1999 Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles J. Magn. Magn. Mater. 201 413-9
5. O'Neala D P et al 2004 Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles Cancer Lett. 209 171-6
6. Gao Z, Kennedy A M, Christensen D A and Rapoport N Y 2008 Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy Ultrasonics 48 260-70
7. Chen J and Wong S T C 2007 Nanotechnology in cancer genomics and proteomics IEEE Signal Process. Mag. 24 111-21
8. Aunoble B, Sanches R, Didier E and Bignon Y J 2000 Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer Int. J. Oncol. 16 567-76
9. Chen J et al 2005 Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents Nano Lett. 5 473
10. Yang P H, Sun X, Chiu J F, Sun H and He Q Y 2005 Transferrin-mediated gold nanoparticle cellular uptake Bioconjug. Chem. 16 494-6
11. Hainfeld J F, Slatkin D N and Smilowitz H M 2004 The use of gold nanoparticles to enhance radiotherapy in mice Phys. Med. Biol. 49 309-15
12. Pothur S and Srivastava S (ed) 2003 Nanotechnology in Disease Detection and Treatment (Amsterdam: IOS Press)
13. Hainfeld J F, Slatkin D N, Focella T M and Smilowitz H M 2006 Gold nanoparticles: a new x-ray contrast agent Br. J. Radiol. 79 248-53
14. Chang M Y, Shiau A L, Chen Y H, Chang C J, Chen H H and Wu C L 2008 Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice Cancer Sci. 99 1479-84
15. Rahman W et al 2008 Radiosensitization by gold nanoparticles in superficial radiotherapy techniques Med. Phys. 35 2716
16. Huang W C, Tsai P J and Chen Y C 2007 Functional gold nanoparticles as photothermal agents for selective-killing of pathogenic bacteria Nanomedicine 2 777-87
17. Patra H K et al 2007 Cell selective response to gold nanoparticles Nanomedicine 3 111-9
18. Kong T et al 2008 Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles Small 4 1537-43
19. Zhang X et al 2008 Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles Clin. Invest. Med. 31 E160-7
20. Sánchez I and Dynlacht B D 2005 New insights into cyclins, CDKs, and cell cycle control Sem. Cell Dev. Biol. 16 311-21
21. Zou H, McGarry T J, Bernal T and Kirschner M W 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis Science 285 418-22
22. Reimann J D et al 2000 Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase-promoting complex Cell 105 645-55
23. Bandara L R et al 1992 Cyclin A recruits p33CDK2 to the cellular transcription factor DRTF1 J. Cell Sci. (Suppl) 16 77-85
24. Brechot C 1993 Oncogenic activation of cyclin A Curr. Opin. Genetics Dev. 3 11-8
25. Goldstone S et al 2001 Cdc25-dependent activation of cyclin A/CDK2 is blocked in G2 phase arrested cells independently of ATM/ATR Oncogene 20 921-32
26. Pagano M et al 1992 Cyclin A is required at two points in the human cell cycle EMBO J. 11 961-71
27. Parshad R, Gantt R, Sanford K K and Jones G M 1984 Chromosomal radiosensitivity of human tumor cells during the G2 cell cycle period Cancer Res. 44 5577-82
28. Iliakis G and Nusse M 1983 Evidence that repair and expression of potentially lethal damage cause the variations in cell survival after x irradiation observed through the cell cycle in Ehrlich ascites tumor cells Radiat. Res. 95 87-107
29. Terasima T and Tolmach L J 1963 Variations in several responses of HeLa cells to x-irradiation during the division cycle Biophys. J. 3 11-33
30. Sanford K K and Parshad R 1999 The contribution of deficient DNA repair to chromosomal radiosensitivity of CHO cells after G2 irradiation Cancer Genet. Cytogenet. 108 38-41
31. Bussink J, Tofilon P J and Brock W A 1996 Repair of chromosome and DNA breaks versus cell survival in Chinese hamster cells Int. J. Radiat. Biol. 70 23-32
32. Formenti S C et al 1999 Concurrent paclitaxel and radiation therapy for breast cancer Sem. Radiat. Oncol. 9 34-42
33. Hennequin C, Giocanti N and Favaudon V 1996 Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells Cancer Res. 56 1842-50
34. Kano Y et al 1998 Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines Oncol. Res. 10 347-54 (Pubitemid 128736332)
35. Zoli W et al 1999 Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines Int. J. Cancer 80 413-6